NASDAQ · GOSS
Healthcare · Biotechnology
$0.14
Up+$0.00 (+0.21%)
Updated Aug 18, 2026, 3:02 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
GOSS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning GOSS.
GOSS research
Company profile and research snapshot.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Piper Sandler | Overweight | — |
| Jul 28, 2026 | Leerink Partners | Outperform | — |
| Jul 27, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 25, 2026 | HC Wainwright & Co. | Buy | — |
| May 26, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 28, 2026
Leerink Partners analyst Joseph Schwartz upgrades Gossamer Bio (NASDAQ:GOSS) from Market Perform to Outperform and maintains the price target from $1 to $1.
Benzinga · Jul 27, 2026
Gossamer Bio plans a September 2026 NDA filing for seralutinib following FDA feedback and reacquires global rights.
Benzinga · Jul 27, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $2 price target.
Benzinga · Jun 25, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $5 to $2.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GOSS.
